pharmaceuticals and global health
DESCRIPTION
Pharmaceuticals and Global Health. Inequalities and Innovation in the 21 st Century. 1 What has been invested in neglected disease R&D?. 2 New business models for global health R&D. 3 Challenges and solutions for the future. Global trends in neglected disease R&D investment. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Pharmaceuticals and Global Health](https://reader035.vdocuments.mx/reader035/viewer/2022081520/568164cb550346895dd6eacf/html5/thumbnails/1.jpg)
Pharmaceuticals and Global Health
Inequalities and Innovation in the 21st Century
![Page 2: Pharmaceuticals and Global Health](https://reader035.vdocuments.mx/reader035/viewer/2022081520/568164cb550346895dd6eacf/html5/thumbnails/2.jpg)
• Levels of funding• Nature of funding
• Product development partnerships• Innovative developing countries• What has been delivered?
• High risk R&D, long development / short political timelines
• Targeted funding to match R&D needs
• Diversification of funding
Improved sustainabilityin global health R&D
Enabling health impact in developing countries
Global trends in neglected disease R&D investment
2New business models for global health R&D
3Challenges and solutions for the future
1What has been invested in neglected disease R&D?
![Page 3: Pharmaceuticals and Global Health](https://reader035.vdocuments.mx/reader035/viewer/2022081520/568164cb550346895dd6eacf/html5/thumbnails/3.jpg)
$2.5-3.3 billion per year in neglected disease R&D between 2007 and 2011
1What has been invested in neglected disease R&D?
![Page 4: Pharmaceuticals and Global Health](https://reader035.vdocuments.mx/reader035/viewer/2022081520/568164cb550346895dd6eacf/html5/thumbnails/4.jpg)
1Which diseases are funded?
HIV/AIDS, 1117, 34%
Malaria, 596, 18%
Tuberculosis, 584, 18%
Dengue, 249, 8%
Diarrhoeal diseases, 169,
5%
Kinetoplastids, 142, 4%
Bacterial Pneu-monia & Menin-
gitis, 107, 3%
Helminths, 90, 3%Salmonella, 48, 1%
Trachoma, 10, 0%Leprosy, 8, 0%
Buruli ulcer, 6, 0%Rheumatic fever, 1, 0%
Platform technologies, 19, 1%
Core funding, 101, 3%Unspecified, 71, 2%
Neglected disease R&D funding by disease, FY2011 (US$m)
2nd tier/semi-commercial
Top tier diseases
3rd tier/diseases
![Page 5: Pharmaceuticals and Global Health](https://reader035.vdocuments.mx/reader035/viewer/2022081520/568164cb550346895dd6eacf/html5/thumbnails/5.jpg)
1Who is investing in neglected disease R&D?
Public sector (HICs and multilaterals);
1877; 62%
Public (LMICs); 72; 2%
Private sector (MNCs); 469; 15%
Private sector (SMEs); 56; 2%
Philanthropic; 571; 19%
Neglected disease R&D funding by sector FY2011 (US$m)
![Page 6: Pharmaceuticals and Global Health](https://reader035.vdocuments.mx/reader035/viewer/2022081520/568164cb550346895dd6eacf/html5/thumbnails/6.jpg)
1Top funders: Average annual funding 2007-2011
1. US NIH $1,159m 2. Bill & Melinda Gates Foundation $506m
3. Pharmaceutical industry $407m 4. European Commission: Research Directorate-General $113m
5. US Agency for International Development (USAID) $83m
6. US Department of Defense (DOD) $80m
7 We l l c o m e Tr u s t $ 7 2 m 8 . U K D e p a r t m e n t f o r I n t e r n a ti o n a l D e v e l o p m e n t ( D F I D ) $ 6 9 m
![Page 7: Pharmaceuticals and Global Health](https://reader035.vdocuments.mx/reader035/viewer/2022081520/568164cb550346895dd6eacf/html5/thumbnails/7.jpg)
2How have developing countries benefitted?
2New business models for neglected disease R&D
Product Development PartnershipsInvolved in 40% of new products for global health R&D in last decade
Innovative Developing CountriesIncreasing government investment in domestic biotech innovation
![Page 8: Pharmaceuticals and Global Health](https://reader035.vdocuments.mx/reader035/viewer/2022081520/568164cb550346895dd6eacf/html5/thumbnails/8.jpg)
MAJOR PHARMACEUTICAL INNOVATIONS
1.MENAFRIVAC2.XPERT MTB/RIF
3.COARTEM
2How have developing countries benefitted?
![Page 9: Pharmaceuticals and Global Health](https://reader035.vdocuments.mx/reader035/viewer/2022081520/568164cb550346895dd6eacf/html5/thumbnails/9.jpg)
MenAfriVac. 56m vaccinated since 2011
Predicted to prevent 437,000 cases in next decade
Pharmaceutical Innovation
2How have developing countries benefitted?
Coartem Dispersible Over 171m delivered to 30+ malaria endemic countries
At costs as low as $0.38 per course of treatment.
Xpert MTB/RIF. Expected to triple diagnosis of drug resistant TB.
India alone, predicted to avert 100,000 deaths/year
Coartem. Since 2001, 400+ mil treatments provided on non-profit basis by Novartis.
Estimated 1mil lives saved.
![Page 10: Pharmaceuticals and Global Health](https://reader035.vdocuments.mx/reader035/viewer/2022081520/568164cb550346895dd6eacf/html5/thumbnails/10.jpg)
360 products in development234 in preclinical, 289 in early clinical, 42 phase III trials
THERE ARE PROMISING CANDIDATES FOR HIV/AIDS, MALARIA, TUBERCULOSIS AND DENGUE
2New business models for neglected disease R&D
![Page 11: Pharmaceuticals and Global Health](https://reader035.vdocuments.mx/reader035/viewer/2022081520/568164cb550346895dd6eacf/html5/thumbnails/11.jpg)
3Challenges and solutions for the future Currently growing pipeline may face untimely funding cuts
R&D pipelines need reliable long-term funding
Financial pressures mean smarter funding needed: Outcome driven and flexible Aligned with product and portfolio developments Coordinated Targeted to deliver the highest health impact
![Page 12: Pharmaceuticals and Global Health](https://reader035.vdocuments.mx/reader035/viewer/2022081520/568164cb550346895dd6eacf/html5/thumbnails/12.jpg)
3Challenges and solutions for the future
Investment in neglected disease = R&D
Improved sustainabilityin global health R&D
Enabling health impact in
developing countries
+
Collaboration & partnerships
Building Capacity in Developing Countries
Quality Research
++ +
Targeted and flexible funding
![Page 13: Pharmaceuticals and Global Health](https://reader035.vdocuments.mx/reader035/viewer/2022081520/568164cb550346895dd6eacf/html5/thumbnails/13.jpg)
Thank you Lindsey Wu Senior Analyst, Policy Cures [email protected]